3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Pancreatic Neoplasms
11
Neoplasms
5
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Metastatic Pancreatic Adenocarcinoma
2
Head and Neck Neoplasms
2
Glioma
2
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Refractory Solid Tumors
1
Pseudomyxoma Peritonei
1
Pancreatic cancer, adult
1
Pancreatic Diseases
1
Oligodendroglioma
1
Neoplasms, Cystic, Mucinous, and Serous
1
Metastatic Adenocarcinoma of the Pancreas
1
Mesothelioma
1
Malignant Solid Neoplasm
1
Locally Advanced Rectal Cancer (LARC)
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Endocrine Gland Neoplasms
1
Disease
1
Digestive System Neoplasms
1
Interventions
Everolimus
7
avelumab
3
Temozolomide
3
Etoposide
3
Cisplatin
3
Bevacizumab
3
pembrolizumab
2
gallium Ga 68 dotatate
2
azaspirane
2
Irinotecan
2
veliparib
1
tocilizumab
1
selinexor
1
pralsetinib
1
pertuzumab
1
pasireotide
1
lenvatinib
1
irinotecan sucrosofate
1
carfilzomib
1
berzosertib
1
belinostat
1
Topotecan
1
TLC 388
1
Radiotherapy
1
Radiosurgery
1
Radionuclide Imaging
1
Positron-Emission Tomography
1
Positron Emission Tomography Computed Tomography
1
Podophyllotoxin
1
Platinum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Neuroendocrine
×
irinotecan sucrosofate
×
Clear all
NCT03837977
2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2
Completed
58 enrolled